Portal hypertension is a frequent pathological symptom occurring especially in hepatic fibrosis and cirrhosis. Current paradigms indicate that inhibition of hepatic stellate cell (HSC) activation and contraction is anticipated to be an attractive therapeutic strategy, because activated HSC dominantly facilitates an increase in intrahepatic vein pressure through secreting extracellular matrix and contracting. Our previous in vitro study indicated that dihydroartemisinin (DHA) inhibited contractility of cultured HSC by activating intracellular farnesoid X receptor (FXR). However, the effect of DHA on fibrosis-related portal hypertension still requires clarification. In this study, gain-and loss-of-function models of FXR in HSC were established to investigate the mechanisms underlying DHA protection against chronic CCl 4 -caused hepatic fibrosis and portal hypertension. Immunofluorescence staining visually showed a decrease in FXR expression in CCl 4 -administrated rat HSC but an increase in that in DHA-treated rat HSC. Serum diagnostics and morphological analyses consistently indicated that DHA exhibited hepatoprotective effects on CCl 4 -induced liver injury. DHA also reduced CCl 4 -caused inflammatory mediator expression and inflammatory cell infiltration. These improvements were further enhanced by INT-747 but weakened by Z-guggulsterone. Noteworthily, DHA, analogous to INT-747, significantly lowered portal vein pressure and suppressed fibrogenesis. Experiments on mice using FXR shRNA lentivirus consolidated the results above. Mechanistically, inhibition of HSC activation and contraction was found as a cellular basis for DHA to relieve portal hypertension. These findings demonstrated that DHA attenuated portal hypertension in fibrotic rodents possibly by targeting HSC contraction via a FXR activation-dependent mechanism. FXR could be a target molecule for reducing portal hypertension during hepatic fibrosis.
Portal hypertension is a frequent pathological symptom occurring especially in hepatic fibrosis and cirrhosis. Current paradigms indicate that inhibition of hepatic stellate cell (HSC) activation and contraction is anticipated to be an attractive therapeutic strategy, because activated HSC dominantly facilitates an increase in intrahepatic vein pressure through secreting extracellular matrix and contracting. Our previous in vitro study indicated that dihydroartemisinin (DHA) inhibited contractility of cultured HSC by activating intracellular farnesoid X receptor (FXR). However, the effect of DHA on fibrosis-related portal hypertension still requires clarification. In this study, gain-and loss-of-function models of FXR in HSC were established to investigate the mechanisms underlying DHA protection against chronic CCl 4 -caused hepatic fibrosis and portal hypertension. Immunofluorescence staining visually showed a decrease in FXR expression in CCl 4 -administrated rat HSC but an increase in that in DHA-treated rat HSC. Serum diagnostics and morphological analyses consistently indicated that DHA exhibited hepatoprotective effects on CCl 4 -induced liver injury. DHA also reduced CCl 4 -caused inflammatory mediator expression and inflammatory cell infiltration. These improvements were further enhanced by INT-747 but weakened by Z-guggulsterone. Noteworthily, DHA, analogous to INT-747, significantly lowered portal vein pressure and suppressed fibrogenesis. Experiments on mice using FXR shRNA lentivirus consolidated the results above. Mechanistically, inhibition of HSC activation and contraction was found as a cellular basis for DHA to relieve portal hypertension. These findings demonstrated that DHA attenuated portal hypertension in fibrotic rodents possibly by targeting HSC contraction via a FXR activation-dependent mechanism. FXR could be a target molecule for reducing portal hypertension during hepatic fibrosis.
Introduction
Portal hypertension is the main complication occurred in hepatic fibrosis and advanced cirrhosis [1] . Hepatic fibrosis exhibits a wound healing process in response to chronic liver injury triggered by various pathological insults, involving pathways of inflammation and fibrogenesis. Activated hepatic stellate cell (HSC) is a dominant fibrotic cell type in the liver due to its disturbance of extracellular matrix (ECM) balance, facilitating secretion of proinflammatory cytokines [2] . Progressive fibrogenesis squeezes hepatic sinusoid and distorts normal liver structure, leading to increased intrahepatic resistance [3] . Contractile force generated from activated HSC is another producer of intrahepatic resistance because of its residence in the space of Disse, wrapping around hepatic sinusoid [1] . As noted above, it is increasingly appreciated that HSC is a critical controller of hepatic vein flow and pressure.
To date, the precise pathological mechanisms of fibrotic portal hypertension have not been entirely explicit. Farnesoid X receptor (FXR) is a main regulator of hepatic fibrosis and portal vein pressure [4] . Further study supported the concept that hepatic FXR expression was downregulated in toxic and biliary cirrhotic rodents and FXR agonist could effectively improve cirrhosis-related portal hypertension [5] . Recently, the role of FXR in alleviating HSC activation and subsequent hepatic fibrosis has been gradually uncovered. FXR À/À mice aged 12 months developed spontaneous hepatic fibrosis [6] . FXR agonist 6-Ethylchenodeoxycholic acid significantly inhibited the expression of a1(I) procollagen in rat primary HSC [7] . FXR ligand GW4064 impressively limited endothelin-1-mediated HSC contraction [8] . However, whether the ameliorative effect of FXR on portal hypertension is attributed to its modulation on HSC contraction is unclear. Dihydroartemisinin (DHA) is derived from natural small-molecular compound artemisinin. Several compounds are synthesized through structural modification of artemisinin, among which DHA is the active metabolite of all artemisinin compounds and has been approved for antimalarial treatment by WHO [9] . In recent years, DHA has attracted attention from researchers for its emerging role in treating liver cancer [10] . Our recent studies for the first time confirmed that DHA prevented liver fibrosis in bile duct-ligated rats by reducing ECM deposition, implying its potential influence on fibrotic portal hypertension [11, 12] . Our subsequent in vitro study also revealed that DHA limited HSC contraction through a FXR-dependent way [13] . However, it remains unclear that the potential effect of DHA on portal hypertension in an in vivo system as well as the mechanisms underlying.
In this study, our data showed that activation of FXR was a prerequisite for DHA to ameliorate CCl 4 -induced liver injury and inflammation. Portal hypertension was also lowered by DHA, which might be associated with alleviated fibrogenesis and inhibited HSC contraction in a FXR activation-dependent approach.
Results
DHA activates FXR in HSC, which facilitates the amelioration of DHA on CCl 4 
-induced liver injury
The effect of DHA on liver injury and the intersection of DHA effect and FXR function were initially evaluated. Immunofluorescence double staining showed that FXR expression in alpha-smooth muscle actin (a-SMA)-positive cells of CCl 4 -stimulated rats was evidently suppressed when compared with the control. DHA, mimicking INT-747 (a specific agonist of FXR), significantly induced FXR expression in HSC. Z-guggulsterone (a specific antagonist of FXR) abolished the effect of DHA. Of interest was that the expression of FXR negatively correlated with a-SMA (Fig. 1B) . Consistently, the expression of FXR in HSC was significantly reduced in human liver tumor samples compared with adjacent tissues (Fig. 1C) . Growth retardation was found in model group but diminished by either DHA or INT-747 treatment and even to a greater degree in DHA and INT-747 cotreatment group. Rats treated with DHA and Z-guggulsterone yet showed significant less weight gain ( Fig. 2A) . Notably, liver index exhibited a reverse trend to the weight gain of rats (Fig. 2B) . DHA improved CCl 4 -caused abnormal high activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and lactate dehydrogenase (LDH) in serum, which was cancelled by Z-guggulsterone (Fig. 2C) . CCl 4 caused great morphological changes, especially the typical fibrotic appearance with extensive nodular formation. DHA and INT-747 treatment improved the pathological changes, while Z-guggulsterone abolished the DHA effect (Fig. 2D ). Hematoxylin and eosin (H&E) staining showed that DHA and INT-747 ameliorated disorder of hepatic lobule structure and hepatic vacuolation. DHA effect was weakened by Z-guggulsterone (Fig. 2E) . FXR knockdown (KD) mice were generated using RNAi technology to genetically testify the role of FXR in mediating the hepatoprotective effect of DHA. Herein, FXR shRNA lentivirus was injected biweekly to silence the expression of hepatic FXR (Fig. 3A) . The interference efficiency of shRNA was determined using immunofluorescence double staining. The results showed that FXR gene silencing in murine HSC was achieved using lentivirus transfection. Of note was that DHA stimulated the expression of FXR and suppressed the expression of a-SMA in wild-type (WT) mice (Fig. 3B) . Besides, DHA improved the structure of liver tissues from CCl 4 -treated WT mice. FXR deficiency aggravated the toxicity of CCl 4 , and more importantly, it neutralized the effect of DHA (Fig. 4) . Altogether, these data demonstrated that DHA protected rats and mice from CCl 4 -induced liver injury through activation of FXR.
Activation of FXR contributes to the therapeutic effect of DHA on liver inflammation during hepatic fibrosis Inflammatory responses occur in various chronic liver diseases throughout the pathological process. The DHA effect on CCl 4 -caused liver inflammation was evaluated. Our results showed a clear increase in the levels of proinflammatory cytokines in serum from group 2 but a significant decrease in those in serum from group 3 and 4. The inhibitory effect of DHA on the secretion of proinflammatory cytokines was consolidated by INT-747 but diminished by Z-guggulsterone ( Fig. 5A-C) . Severe inflammatory cell infiltration in the liver exposed to CCl 4 was suppressed by DHA and INT-747 administration, characterized by reduced intrahepatic CD45-and F4/80-positive cells. Z-Guggulsterone neutralized the DHA effect (Fig. 5D) . Intriguingly, genetic inhibition of FXR, analogous to pharmacological approach, also weakened the antiinflammatory effect of DHA and resulted in aggravated inflammatory cell infiltration (Fig. 6A,B) . CCl 4 aroused the elevation of hepatic tumor necrosis factoralpha (TNF-a), nuclear factor-kappa B (NF-jB), and nucleotide binding oligomerization domain-like receptor family, pyrin domain containing 3 (NLRP3) expression and restricted I kappa B-alpha (IjB-a) expression. DHA and INT-747 treatment cancelled the For the statistics in this figure, data were expressed as mean AE SD. P values were determined using one-way ANOVA with the post hoc Dunnett's test. ## P < 0.01 versus adjacent nontumorous tissues, ### P < 0.001 versus group 1, **P < 0.01 and ***P < 0.001 versus group 2, $ P < 0.05 versus group 3.
proinflammatory effect of CCl 4 while Z-guggulsterone cancelled the DHA effect (Fig. 5E ). Immunofluorescence staining was visually consistent with the results above (Figs 5F and 6C). Collectively, our results showed that FXR activation was a prerequisite for DHA to ameliorate severe liver inflammation.
Activation of FXR mediates the suppression by DHA of portal hypertension in fibrotic rats and mice Next, we investigated the effect of DHA on portal hypertension. Results showed that portal vein pressure was obviously increased in fibrotic rats but decreased by DHA and INT-747 treatment. Z-guggulsterone impaired the curative effect of DHA (Fig. 7A ). This result was consistent with that obtained from FXR KD mice, showing a weak effect of DHA on portal pressure (Fig. 8) . Mean arterial pressure was significantly lower in fibrotic rats than that in vehicle-treated rats, indicating of hyperdynamic state under CCl 4 administration. DHA and INT-747 treatment exerted little effect on normalizing the mean arterial pressure, suggesting their primary intrahepatic effects (Fig. 7B) . Total intrahepatic vascular resistance was also increased in fibrotic rats compared with the control, H&E staining (original magnification, 209). Scale bar = 100 lm. For the statistics of each panel in this figure, data were expressed as mean AE SD. P values were determined using one-way ANOVA with the post hoc Dunnett's test. ### P < 0.001 versus group 1, *P < 0.05, **P < 0.01, and ***P < 0.001 versus group 2, $ P < 0.05 and $$ P < 0.01 versus group 3.
characterized by higher perfusion pressure both in general and in part (Fig. 7C ). Collectively, these data suggested that DHA improved portal hypertension by FXR activation.
FXR activation facilitates the ameliorative effect of DHA on hepatic fibrosis
Hepatic fibrogenesis is a major inducer of portal hypertension. DHA significantly reduced the CCl 4 - induced high levels of hyaluronic acid (HA), laminin (LN), procollagen type III (PC-III), and collagen type IV (C-IV) in serum, which was abolished by Z-guggulsterone (Fig. 9A ). Masson and Sirius red staining showed that DHA reduced the CCl 4 -caused excessive collagen deposition, which was suppressed by Z-guggulsterone (Fig. 9B ). Consistent result was obtained by detecting hepatic hydroxyproline (Fig. 9C) . Compared with WT mice, FXR KD mice when chronically challenged with CCl 4 were characterized by higher degrees of fibrotic lesions and the antifibrotic effect of DHA was reduced on FXR KD mice (Fig. 10A,B ). DHA reduced the high level of TGF-b in serum caused by CCl 4 , which was inhibited by Z-guggulsterone (Fig. 11A) . DHA also reduced the expression of fibrotic genes, which, however, was abrogated by Z-guggulsterone (Fig. 11B,C) . The expression of plateletderived growth factor receptor-beta (PDGFR-b), epidermal growth factor receptor (EGFR), and transforming growth factor-beta receptor type I (TGF-bRI) was evaluated and the results were consistent with our results above (Fig. 11D) . Immunofluorescence staining confirmed the results of western blot. Peroxisome proliferator-activated receptor-gamma (PPARc) was also visualized for distinguishing the phenotype of HSC (Fig. 12) . Noteworthily, DHA inhibited the expression of fibrotic genes, facilitated the expression of PPARc, and reversed the phenotype of HSC in CCl 4 -treated WT mice, which, however, was not achieved in FXR KD mice (Fig. 13A,B) . In summary, these findings uncovered that DHA inhibited HSC activation and consequent hepatic fibrosis through regulating FXR.
Activation of FXR is a prerequisite for DHA to limit HSC contraction and consequently lower portal vein pressure
To identify whether limitation of HSC contraction was involved in the therapeutic effect of DHA on portal hypertension, the expression of contraction-related protein was evaluated using immunofluorescence double staining. As expected, phospho-myosin light chain (p-MLC), myosin light chain kinase (MLCK), phosphomyosin phosphatase target subunit 1 (p-MYPT1), rhoassociated kinase (ROCK), and sphingosine-1-phosphate receptor 2 (S1PR2) were significantly increased in HSC from fibrotic livers but decreased in HSC from DHAand INT-747-treated rat livers. The ameliorative effect of DHA was further strengthened by INT-747 but abrogated by Z-guggulsterone (Figs 14 and 15) . Genetically, specific inhibition of FXR by shRNA also abolished the suppressive effect of DHA on MLC phosphorylation (Fig. 16) . In general, all the results above revealed that DHA suppressed portal hypertension by promoting HSC relaxation in a FXR-dependent way.
Discussion
Portal hypertension, as a consequence of chronic liver diseases, heralds the onset of the most lethal complication of fibrosis and cirrhosis. Portal hypertension is characterized by abnormally elevated intrahepatic vein pressure, which comes from various etiological factors. Intrahepatic causes, especially hepatic fibrosis, are main triggers of portal hypertension. Additionally, activated HSC also affects intrahepatic vascular resistance and pressure by contracting. Complicated pathogeneses of portal hypertension lead to deficiency in the development of corresponding drug treatment. Our work was aimed to evaluate whether DHA was a potential reagent for relieving portal hypertension based on its precise efficacy on hepatic fibrosis [11] . Meanwhile, FXR gain-and loss-of-function models were applied to further identify the underlying mechanisms.
Mechanistic studies over the past decades have highlighted the role of FXR in the intervention of hepatic fibrosis and portal hypertension [5, 14] . To evaluate the effect of DHA on fibrosis-related portal hypertension, in vivo models of experimental fibrosis were established by CCl 4 injection. Chronic CCl 4 administration at low dose causes experimental hepatic fibrogenesis, which largely imitates clinical hepatic fibrosis [15] . The protective effect of DHA on liver injury and the role of FXR involved were firstly measured for that CCl 4 mainly attacks hepatocytes and leads to severe liver injury. Growth is a preliminary indicator for physical condition which will be arrested when rats are diseased. The established serum biomarkers are also monitored for their sensitivity to liver injury, which will leak in quantity from damaged hepatocytes into the circular system [16] . H&E staining is a regular method for visualizing the structural integrity of the liver. In this study, we observed a dramatic DHAcaused reversal of hepatic histological injury. INT-747, as an exogenous FXR ligand, also exerted corresponding therapies by activating FXR, which was consistent with the previous study [17] . DHA further enhanced the effect of INT-747. Nevertheless, Z-guggulsterone abrogated the DHA effect which could be attributed to its inhibitory effect on FXR activation.
Sustained liver injury often comes with inflammatory responses, stimulating the progression of hepatic fibrosis. Hepatocytes injured by CCl 4 injection are forced to undergo cell death, where cellular debris is engulfed by macrophages and HSC. Massive proinflammatory cytokines are produced, among which TNF-a, interferon-gamma (IFN-c) , and interleukin-6 (IL-6) are dominant players in hepatic inflammation and fibrosis. TNF-a, released from polarized macrophages, further accelerates hepatocyte death and promotes HSC survival [18] . The role of IFN-c in the fibrosis was ambiguous. Suppression or lack of IFN-c expression is found to attenuate liver inflammation and fibrosis, irrespective of its etiology [19, 20] . Besides, IFN-c inhibited HSC activation in experimental fibrosis, and a trial of IFN-c has begun for hepatitis C-caused advanced clinical fibrosis [21, 22] . Therefore, elevation in serum IFN-c might be a beneficial response for preventing CCl 4 -induced liver injury and HSC activation. HSC also promotes B cell survival, which in turn produces proinflammatory cytokines, such as IL-6, and accelerates liver fibrosis [23] . Chemoattractants, such as TNF-a and IL-6, recruit and aggravate infiltration of CD45 + leucocytes and F4/ 80 + macrophages [24] . NF-jB signaling when activated induces hepatic fibrosis via macrophagemediated chronic inflammation [25] . IjB-a serves as a specific inhibitory protein of NF-jB. NLRP3 inflammasome activation leads to serious liver inflammation and fibrogenesis in mice, characterized by neutrophilic infiltration and HSC activation with intrahepatic collagen deposition [26] . Our work presented that DHA and INT-747 improved liver inflammation in rats. Coactivation of FXR by DHA together with INT-747 further reduced the expression of proinflammatory factors and inflammatory cell infiltration. Z-Guggulsterone yet cancelled the DHA effect, which postulated that DHA stimulation on FXR activity was abolished by Z-guggulsterone, impairing its anti-inflammatory effect.
Continuous hepatic injury and inflammation lead to the occurrence of HSC activation and hepatic fibrogenesis. Hepatic fibrogenesis is known as a main anatomical inducer of portal hypertension. On this basis, fibrogenesis was evaluated. Serum levels of HA, LN, PC-III, and C-IV are the most sensitive indicators for hepatic fibrosis, which have an important diagnostic value for judgment of the disease progression and curative outcomes of therapies [27] . Fibrosis is characterized by excessive intrahepatic collagen deposition. In this study, deposition of collagen was qualitatively visualized by Masson and Sirius red staining and semiquantitatively by western blot. Proliferation and activation of HSC are the core events in liver fibrosis. Abundant cytokines secreted from HSC through autocrine and paracrine, PDGF, EGF, and TGF-b of note, are reported to in turn stimulate HSC activation and proliferation and enhance ECM deposition. Upregulated corresponding receptors, such as PDGFR-b, EGFR, and TGF-bRI, undertake the signaling transductions from their ligands, stimulating HSC activation, proliferation, and hepatic fibrosis [28] . Quiescent HSC is marked by abundant intracellular PPARc while activated HSC is PPARc-deficient [29] . Our results concluded that DHA suppressed the expression of profibrogenic factors and corresponding receptors. Directly, HSC activation and collagen deposition were also alleviated by DHA. Mechanically, the antifibrotic effects of DHA relied on FXR activation and might contribute to its protection against portal hypertension.
Hepatic stellate cell has emerged as an important regulator of hepatic vein flow and intrahepatic resistance via contraction and relaxation [1] . HSC when activated undergoes a phenotypic switch from quiescent to contractile myofibroblastic phenotype, which contributes to continuous increased intrahepatic vein resistance and portal hypertension. Relieving HSC contraction is anticipated to be a novel promising therapeutic strategy for portal hypertension [30] . HSC contraction is facilitated by p-MLC, which is modulated by Ca 2+ -dependent and Ca 2+ -sensitization signaling pathways. Both of the pathways are regulated by S1PR2 in smooth muscle cells [31] . Noteworthily, S1PR2 was recently found to be a novel regulator of human fibroblast contractility [32] . Besides, S1PR2 expression was significantly induced in primary HSC from bile duct-ligated fibrotic mice, while knockout of S1PR2 protected mice from hepatic fibrosis and related portal hypertension [33] . These intriguing discoveries highlighted the potential role of S1PR2 in modulating portal pressure via stimulating hepatic fibrogenesis and HSC contraction. A Ca 2+ -dependent pathway is triggered by activated MLCK, which could phosphorylate MLC. MYPT1, a MLCP subunit, is a key activator of a Ca 2+ -sensitization pathway which when phosphorylated could inhibit MLCP activity and MLC dephosphorylation. ROCK could promote MYPT1 phosphorylation [34] . The molecules mentioned have been recognized as important markers of HSC contraction [35] . Our prior in vitro study found that S1PR2 turned on the transductions of Ca 2+ -dependent and Ca
2+
-sensitization pathways and mediated HSC contraction [13] . In this in vivo work, our results confirmed that DHA limited HSC contractility by inhibiting S1PR2, p-MYPT1, ROCK, MLCK, and p-MLC in rat HSC. Of note, FXR activation played a critical role in mediating the DHA effect.
Interestingly, in this work, we observed an obvious enhancement of antifibrotic effects and antihypertensive effects after DHA treatment in the presence of INT-747. So far, we could not draw such an arbitrary conclusion that FXR was a direct target molecule of DHA based on current data. DHA as a naturally occurring small molecule compound could have multiple targets within cells. Thus, it could be postulated that additional mechanisms was involved in DHA effects, which might lead . n = 8/group. Immunofluorescence double staining for PDGFR-b, TGF-bRI, EGFR, and PPARc with a-SMA of liver sections (original magnification, 409). Scale bar = 100 lm. For the statistics of each panel in this figure, data were expressed as mean AE SD. P values were determined using one-way ANOVA with the post hoc Dunnett's test. ### P < 0.001 versus group 1, **P < 0.01 and ***P < 0.001 versus group 2, $ P < 0.05, $$ P < 0.01, and $$$ P < 0.001 versus group 3.
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The FEBS Journal 284 (2017) 114-133 ª 2016 Federation of European Biochemical Societies to inhibition of HSC activation and contraction. Previous study revealed that Akt activation could be inhibited by FXR [36] . On this basis, it could be speculated that INT-747 exerted its antifibrotic effects via modulating FXR/Akt signaling. Of note was that our previous findings demonstrated that DHA suppressed the signal transduction of Akt pathway, which facilitated the effect of DHA on stimulating HSC apoptosis 
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The FEBS Journal 284 (2017) 114-133 ª 2016 Federation of European Biochemical Societies [11] . Therefore, the direct inhibition of DHA on Akt activation might further strengthen the antifibrotic effects of INT-747. The synergistic phenomenon could also be explained by another possibility that DHA and INT-747 did not competitively bind to the target molecule FXR. They probably targeted the molecule uncompetitively and produced synergistic effects. Although the precise mechanisms underlying DHA function required further in-depth studies, there was no doubt that FXR activation was a prerequisite for DHA to attenuate hepatic fibrosis and portal hypertension. Given that both DHA and INT-747 had potential in the intervention of hepatic fibrosis and portal hypertension, the advantages and disadvantages of both efficient pharmaceutical agents were discussed. The clinical efficacy of INT-747 has been identified in several clinical trials. INT-747 administration for 12 months in patients with primary biliary cholangitis, formerly called primary biliary cirrhosis that can progress to cirrhosis and cause death, resulted in significant decreases in ALP and total bilirubin levels when compared with placebo administration [37] . In the phase II trial, administration of 25 or 50 mg INT-747 for 6 weeks was well tolerated, increased insulin sensitivity, and reduced markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease [38] . However, the side effect of INT-747 was a noticeable problem. INT-747 administration, especially in high doses, would cause severe pruritus, which was the main reason for the withdrawal of this agent. DHA-piperaquine has been identified as an artemisinin combination therapy recommended by WHO for the treatment of uncomplicated malaria. Its efficacy assessed over 28-63 days has consistently exceeded 95% in the treatment of multidrug-resistant falciparum malaria. Efficacy and tolerability of this combination therapy in over 2600 patients were uniformly good, and no serious adverse effects, such as renal injury, were observed [39, 40] . In addition, the influences of DHA-piperaquine combination therapy for uncomplicated malaria on hemodynamics, electrocardiography, and blood sugar levels were not significant, highlighting its safety and effectiveness [41] . So far, studies have not conducted on evaluating the clinical efficacy of DHA on liver fibrosis. Our previous preclinical studies innovatively confirmed the antifibrotic effects of DHA by inhibiting HSC activation and inducing HSC apoptosis [11, 12] . Also, DHA limited the contractility of HSC in in vitro system, while the growth of hepatocytes was not affected [11, 13] . However, the precise molecular mechanisms underlying DHA effects have not illuminated that constrains the clinical development of DHA in treating liver diseases. Of note that DHA was defined as an innocuous and effective agent based on the available studies, the therapeutic potential of DHA should be further studied.
In conclusion, our present work demonstrated that DHA improved liver injury, inflammation, fibrogenesis, and portal hypertension in fibrotic rats. Mechanistically, DHA ameliorated portal hypertension by inhibiting HSC activation-led fibrosis and HSC contraction-induced increase in intrahepatic vein resistance in a FXR-dependent mechanism. These novel discoveries not only provided an excellent candidate for the treatment of fibrosis-related portal hypertension but also uncovered the potential mechanisms involved. . n = 8/group. Immunofluorescence double staining for MLCK, p-MYPT1, ROCK, and S1PR2 with a-SMA of liver sections (original magnification, 409). Scale bar = 100 lm. For the statistics of each panel in this figure, data were expressed as mean AE SD. P values were determined using one-way ANOVA with the post hoc Dunnett's test. ### P < 0.001 versus group 1, *P < 0.05, **P < 0.01, and ***P < 0.001 versus group 2, $ P < 0.05 and $$ P < 0.01 versus group 3.
Materials and methods

Reagents and antibodies
Dihydroartemisinin was purchased from Sigma-Aldrich (St Louis, MO, USA) and dissolved in olive oil. INT-747 was purchased from SelleckChem (Houston, TX, USA) and dissolved in freshly prepared 1% methylcellulose. Z-Guggulsterone was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Z-Guggulsterone was dissolved in dimethylsulfoxide and diluted in 1% methylcellulose as previously described [42] . Lentiviral vectors encoding control shRNA and FXR shRNA were purchased from Sigma-Aldrich. The primary antibodies against CD45, F4/80, TNF-a, NF-jB, EGFR, TGF-bRI, FXR, PPARc, p-MLC, p-MYPT1, S1PR2, and b-actin were purchased from Santa Cruz Biotechnology. The primary antibodies against IjB-a, MLCK, and ROCK were purchased from Proteintech Group, Inc. (Rosemont, IL, USA). The primary antibody against NLRP3 was purchased from Abcam (Cambridge, MA, USA). The primary antibodies against a-SMA, fibronectin, and a1(I) procollagen were purchased from Epitomics (San Francisco, CA, USA). The primary antibody against PDGFR-b and the horseradish peroxidase-conjugated secondary antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). The primers used in quantitative real-time polymerase chain reaction (qRT-PCR) were purchased from GenScript Co. Ltd. (Nanjing, Jiangsu, China).
Human liver samples
Liver biopsies from patients with liver cancer (n = 4) were randomly selected from Oncology Department, Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China. Both human liver tumor tissues and adjacent nontumorous tissues were obtained and examined. Studies were conducted in accordance to National Institutes of Health and institutional guidelines for human subject research.
Experimental animal procedures
All experimental procedures were approved by the institutional and local committee on the care and use of animals of Nanjing University of Chinese Medicine (Nanjing, Jiangsu, China), and all animals received human care according to the National Institutes of Health guidelines.
Study I
Forty-eight male Sprague-Dawley rats (200 AE 20 g) were purchased from Zhejiang Academy of Medical Sciences (Hangzhou, Zhejiang, China) and randomly divided into six groups (eight rats/group) and received corresponding treatment (Fig. 1A) . In detail, a mixture of carbon tetrachloride (CCl 4 ; 0.1 mL/100 g bodyweight) and olive oil [1 : 1 (v/v)] was introduced to generate fibrotic rats as we previously described [43] . Group 1 was the vehicle control in which rats were not administrated with any treatments but intraperitoneally injected with the vehicle olive oil. Group 2-6 were model and treatment groups in which rats were i.p. injected with CCl 4 every other day for 8 weeks. Rats in group 3, 4, 5, and 6 were, respectively, administrated with DHA, INT-747, DHA plus INT-747, and DHA plus Z-guggulsterone within last 4 weeks. DHA was delivered by intraperitoneally injection at 7 mgÁkg À1 once daily for five consecutive days per week. INT-747 was delivered by intragastric gavage at 30 mgÁkg À1 once daily. Z-Guggulsterone was delivered by intraperitoneally injection at 10 mgÁkg À1 once daily.
Study II
Sixty male ICR mice (20-25 g) were purchased from Nantong University (Nantong, Jiangsu, China). FXR shRNA lentivirus with a titer of 1 9 10 8 TU/mice was biweekly injected into murine caudal vein to establish FXR KD mice as described in our previous study [44] . Control mice, which were challenged with neither CCl 4 nor DHA, were intraperitoneally injected with an equal volume of olive oil. All animals had free access to chow diet as well as water and were kept at 21-25°C under a 12-h dark/light cycle. Twenty-four hours after the last CCl 4 administration, animals were weighed and blood was collected. Animals were then sacrificed after anesthetization by intraperitoneally injection with pentobarbital (50 mgÁkg À1 ). Rat and murine livers were harvested and weighed. A small portion of each liver was fixed by 10% neutral buffered formalin and embedded with paraffin for histological and immunohistochemical studies. The remaining liver was rapidly frozen in liquid nitrogen for immunofluorescence staining and extraction of total RNA and protein.
Liver histopathology
Hematoxylin and eosin and Masson's trichrome staining were performed using standard methods. Sirius red staining was performed as our previous description [43] . Immunohistochemical and immunofluorescence staining were conducted as previously described [24] . Photographs were taken in a blinded fashion at random fields. Morphometric analysis was conducted using semiquantitative IMAGE PRO-PLUS software (Media Cybernetics, Inc., Silver Spring, MD, USA). Fluorescent intensity was analyzed using IMAGE J Software 2.0.0 (National Institutes of Health, Bethesda, MD, USA).
Biochemical analysis
Sera were separated from whole blood after centrifugation. Activities of serum AST, ALT, ALP, and LDH were detected using commercial assay kits according to the protocols from manufacturer (Nanjing Jiancheng Bioengineering Institute, Nanjing, Jiangsu, China). The absorbance values were determined using a SpectraMax ™ microplate spectrophotometer (Molecular Devices, Sunnyvale, CA, USA).
Determination of the content of hepatic hydroxyproline
The contents of hydroxyproline in liver tissues were measured by a commercial kit (Nanjing Jiancheng Bioengineering Institute) according to the protocol from manufacturer.
The absorbance values were detected using a SpectraMax ™ microplate spectrophotometer.
Enzyme-linked immunosorbent assays (ELISA)
The levels of IFN-c, TNF-a, IL-6, HA, LN, PC-III, C-IV, and TGF-b in serum were determined by corresponding ELISA kits according to the protocols from manufacturer (Nanjing SenBeiJia Biological Technology Co., Ltd., Nanjing, Jiangsu, China). The absorbance was read using a SpectraMax ™ microplate spectrophotometer.
Determination of vascular pressure and intrahepatic resistance
Measurement of hepatic portal pressure and mean arterial pressure was performed under pentobarbital anesthesia by cannulation of portal vein and carotid artery as previously described [5] . For measurement of intrahepatic vascular resistance, an in-situ flow-controlled liver perfusion was introduced as previous description [45] . The perfusion pressure was continuously monitored by a pressure transducer.
Quantitative real-time polymerase chain reaction RNA isolation and qRT-PCR were performed as we previously described [24] . Glyceraldehyde phosphate dehydrogenase (GAPDH) was used as the invariant control and the mRNA expression of target genes was expressed as fold changes after normalization to GAPDH. The primers were constructed referring to our previous study [43] . All experiments were performed as triplicate.
Western blot analysis
Protein extraction and western blot analysis were performed as we previously described [24] . b-Actin was used as the invariant control. The abundance of target proteins was accurately identified using QUANTITY ONES 4.4.1 (BioRad Laboratories, Berkeley, CA, USA) and expressed as fold changes after normalization to b-actin. All experiments were performed as triplicate.
